Laboratory Nexus is offering a newly built, fully equipped, high-complexity molecular diagnostics laboratory in Pennsylvania, ready to operate on day one. The facility, instrumentation, and CLIA licensure are already in place, so a buyer can skip the 12 to 24+ months typically needed for build-out, instrument procurement, and assay validation.
This is an asset and infrastructure sale. No revenue, customer relationships, or active billing operations are included. The value of this opportunity is the turnkey facility itself.
Key Highlights
– Newly constructed, purpose-designed molecular laboratory space
– CLIA-licensed for high-complexity testing
– PacBio Vega HiFi long-read sequencing platform, installed and operational
– Applied Biosystems QuantStudio 6 real-time PCR system, paired with Veriti thermal cyclers
– Validated NGS test menu for Pharmacogenomics (PGx) and Cancer Genetics (CGx)
– Ultra-low-temperature sample storage and organized inventory infrastructure in place
What’s Included
– Complete facility build-out: lab suites, dedicated bench space, and reception/administrative areas
– All installed laboratory instrumentation, including the PacBio Vega HiFi sequencer and QuantStudio 6 real-time PCR system
– Completed CLIA high-complexity licensure
– Validated PGx and CGx assay protocols (NGS-based)
– Sample storage and inventory infrastructure
What’s Not Included
– Revenue, billing history, or active testing volume
– Existing customer, physician, or referral relationships
Ideal Buyer
– A group entering molecular diagnostics without the lead time of a ground-up build-out
– An existing laboratory expanding high-complexity or NGS testing capacity
– An investor seeking a ready-made operational platform for a molecular diagnostics business
Confidentiality
This listing is presented on a confidential basis. The exact facility location and complete equipment specifications are shared with qualified parties after signing a Non-Disclosure Agreement (NDA).
Interested? Speak with our team to schedule a consultation and learn more about this opportunity.
